Every August through the 1990s, Korean urology clinics filled up with boys. Summer vacation was circumcision season. Fathers brought sons, sons brought classmates, and the waiting rooms ran on a schedule as fixed as the school calendar. Roughly eight in ten Korean men born in that era went through it. Consequently, an entire medical specialty built its cash flow around one childhood ritual.
That ritual is now largely gone. Korean media put the current rate near 20 percent, down from around 80 percent in the early 2000s. In other words, the Korea urology industry lost its most reliable revenue line inside a single generation.
What happened next is the interesting part. Rather than shrinking, the specialty found a much larger customer. That customer is the ageing male body. Prostate disease, kidney stones, incontinence and robot-assisted cancer surgery have replaced the summer rush across the Korea urology industry. Meanwhile, the clinics have changed names, changed marketing and changed the kind of doctor they attract.
For anyone reading Korean healthcare as a business rather than a service, this is one of the cleanest case studies available.
Circumcision arrived in Korea with the American military presence after 1945. It was never traditional. Nevertheless, within two decades it had been absorbed into Korean life as a marker of growing up. It even acquired its own slang and its own season.
Then the consensus cracked. Korean doctors began publishing dissenting reviews. Online communities picked up the argument. Parents started asking questions nobody had asked their own fathers. Today Korea sits in an unusual cluster of high-circumcision countries alongside the United States, Israel and the Philippines. Most of Europe and Japan, by contrast, stay under a few percent.
The commercial consequence was immediate. A neighbourhood clinic that once booked dozens of identical procedures each summer suddenly faced empty August afternoons. Worse, the procedure had also worked as a customer-acquisition tool. A boy who visited at twelve knew where to go at thirty.
Losing that funnel forced a strategic question on thousands of small practices. Specifically: what does a urologist sell in a country that no longer wants the thing urologists used to sell?
The first answer was cash cosmetic surgery. Through the 2000s and 2010s, several network brands scaled nationally on male enhancement and premature-ejaculation procedures. None of it was covered by insurance, and all of it was marketed aggressively. Those networks have since contracted sharply. Demand moved, and so did the doctors. The Korea urology industry had found its second business model, and it did not last either.
Scale first, because the numbers are smaller than most people assume.
Korea has roughly 2,300 practising urologists, according to specialty association estimates. About two-thirds of them run their own clinics rather than working inside hospitals. By comparison, dermatology and plastic surgery attract far more attention and far more capital. Urology is a small, fragmented, owner-operated trade.
It is also unusually exposed to policy. The specialty sits near the bottom of the national health insurance billing tables. That means clinic revenue depends heavily on procedures the public system either prices poorly or does not cover at all. As a result, the economics of Korean urology clinics turn on a handful of specific line items rather than on raw patient volume.
One structural detail matters here. Korea has no gatekeeping system, so patients walk into specialist clinics directly. Therefore a urology clinic competes for footfall the way a café does. That is why they cluster around subway exits and office districts rather than around hospitals.
The result is a two-track industry. University hospitals handle cancer and complex surgery. Meanwhile, small private clinics handle everything else and compete on convenience.
| Shift | Old model (1990s–2000s) | Current model (2020s) |
|---|---|---|
| Anchor procedure | Circumcision | Prostate and urinary care |
| Core patient | Boys and young men | Men over 50 |
| Payment | Cash, seasonal | Insurance plus private-insurance-backed procedures |
| Marketing | Word of mouth | Search, YouTube, clinic branding |
| Growth driver | Birth cohort size | Population ageing |
Training numbers tell the same story from the supply side.
Urology spent the 2010s as one of Korea’s least wanted specialties. Residency slots went unfilled year after year from 2011 onward. The professional body eventually concluded that the field had over-produced doctors, and in 2017 it cut the national training quota from 120 places to 78. It then held recruitment near 50 for several years afterwards.
That decision now looks aggressive. Applications recovered as soon as the prostate wave arrived, and the specialty filled its quota again in 2023 for the first time in a decade. Some teaching hospitals reported oversubscription. Workforce projections presented to the association, meanwhile, warned of a specialist shortage by 2035 as demand keeps rising against a deliberately shrunken pipeline.
The geography compounds it. Seoul and Gyeonggi absorb most new clinics, while smaller cities struggle to replace retiring urologists. Rural patients consequently present later, which shows up directly in cancer staging. A nationwide hospital study found the high-risk share at diagnosis running several points higher outside major cities.
For the Korea urology industry, that imbalance is both a public health problem and a competitive fact. Demand is national; supply is metropolitan.
Demographics did the heavy lifting. Korea is ageing faster than any other developed country, and prostate disease scales directly with that curve.
The benign side came first. Roughly 1.61 million Korean men over 50 received treatment for benign prostatic hyperplasia in 2024. Five years earlier the figure stood near 1.31 million. That is steady compounding growth in a country whose total population is falling.
The malignant side arrived louder. Prostate cancer became Korea’s leading male cancer in 2023, overtaking lung and stomach. New cases reached 23,928, against 11,095 in 2014. Adjusted for population ageing, incidence still climbed 43 percent between 2006 and 2023.
Yet Korea runs no national prostate screening. Women receive institutionalised breast and cervical programmes; men receive nothing equivalent. PSA testing therefore sits outside the national system, which leaves early detection to men who seek it out and pay for it themselves.
The distributional effect is stark. Men in the top income bracket were diagnosed at 191 cases per 100,000. Among men in the seventh income decile, the rate was 27. Early diagnosis, in short, has become a purchased good.
Urologists have spent two years lobbying to change that. Their societies proposed national PSA screening starting at age 55, arguing it would narrow regional gaps and reduce the cost of late-stage care. Government researchers, meanwhile, moved the other way. A National Health Insurance Service institute listed PSA testing for men aged 75 and older among 31 candidate indicators of “low-value care.” The Korean Urological Association objected immediately. Screening decisions, it argued, depend on life expectancy rather than on chronological age.
Both sides are arguing about the same thing: who pays for finding cancer early. For the Korea urology industry, the answer determines a decade of case volume.
Follow the private insurance rather than the public system, and the picture sharpens.
About seven in ten Koreans hold silson indemnity insurance, a private top-up that reimburses out-of-pocket medical costs. It has quietly become the funding engine for procedures the national system does not cover. Urology found its own such procedure in the prostatic urethral lift, sold in Korea under names like UroLift.
The device props the prostate open using small implants. It is quick, done under local anaesthetic, and it preserves sexual function better than older resection surgery. However, national insurance does not cover it. Korean price surveys put the procedure in the three-to-six-million-won range. The covered alternative, transurethral resection, costs a fraction of that.
Insurers noticed the pattern. A 2024 investigation by Asia Business Daily described patients travelling from across the country to a single clinic for the uncovered procedure. One man, according to that report, paid 16 million won for a bundle that included cosmetic surgery recorded on paper as something else. Regulators have since flagged the specialty for using the implant outside its intended patient group.
This is the uncomfortable centre of the Korea urology industry. A genuine clinical need, an ageing patient base and a permissive private-insurance layer have combined into a category that grows faster than anyone can audit it. Korea’s health insurance system earns international praise for cost control. Even so, the uncovered margin keeps expanding around its edges.
Reform is already moving. Insurers are tightening claims review, and a restructured indemnity product is designed to curb exactly this behaviour. For clinic owners, that represents the single largest business risk of the next five years.
Hospital urology runs on entirely different economics from the clinic side of the Korea urology industry.
Robotic surgery reached mainstream Korean practice through prostate cancer. The gland sits deep in the pelvis, beside nerves that determine continence and sexual function. Precision therefore matters more here than almost anywhere else in the body. Consequently, the da Vinci platform became standard for radical prostatectomy at major centres.
The equipment is not covered by national insurance either. Patients typically pay around ten million won out of pocket. That places robotic surgery in the same private-insurance category as the office procedures downstairs. Intuitive Surgical’s Korean subsidiary posted about 253 billion won in 2024 revenue, up from roughly 213 billion won a year earlier. Consumables drove much of the gain, since the instruments must be replaced after a set number of uses.
Outcomes deserve honesty, though. Korea Biomedical Review has reported that robotic prostatectomy still leaves roughly 30 percent of patients with incontinence and about half with erectile dysfunction. Robots reduce harm; they do not eliminate it. That gap is precisely why urologists keep pushing for earlier detection, because early-stage disease needs less aggressive treatment in the first place.
Access varies as well. Robotic surgery rates differ by region and by income, which reproduces the screening inequality one step further along the pathway. Anyone tracking Korea’s medical AI and digital health sector will recognise the pattern. New technology arrives first where the money already is.
In 2017 the specialty renamed itself. The Korean term shifted from binyogigwa, which reads roughly as “urinary organ department,” to binyouihakgwa, meaning “urological medicine.” The goal was to shed a reputation as a men-only clinic.
It has not worked especially well. A 2022 survey by the urological society found that 70.3 percent of respondents still assumed urology treats men. Only 26.3 percent said it treats everyone. Korean women with bladder infections or incontinence therefore go to gynaecologists instead.
That misperception costs the specialty real revenue. Female urology covers incontinence, overactive bladder and recurrent infection. It is a large, underserved market that Korean urology clinics mostly fail to capture.
The most effective correction came from YouTube rather than from any professional campaign. A urologist named Hong Sung-woo built a mass audience by discussing sexual health in blunt, comic, profanity-laced Korean. He appears across mainstream television, and he consistently corrects hosts who use the old department name. His channel arguably did more to normalise the conversation than a decade of official statements. He has also drawn criticism for appearing alongside supplement advertising, which is its own comment on the sector’s incentives.
Destigmatisation, it turns out, is a growth strategy. Younger Korean men now book appointments for problems their fathers ignored entirely.
Behind the marketing of the Korea urology industry sits ordinary clinical work.
Sexually transmitted infections form a steady share of it, and syphilis in particular has returned. Korea recorded 2,786 syphilis patients in a recent surveillance year. Men accounted for 78.0 percent of cases, with a male incidence rate of 8.5 per 100,000 against 2.4 for women. Multiplex testing panels moved into national insurance coverage several years ago, which shifted this work from cash to claims.
Kidney stones supply the other reliable stream. Korean summers are brutally humid, dehydration is common, and stone attacks spike accordingly. Several larger clinics now advertise 24-hour stone service. The pain arrives without warning, after all, and patients go to whoever is open.
Male fertility testing has grown too, for reasons tied to Korea’s demographic squeeze. Couples marry later and seek fertility treatment sooner. Male-factor evaluation now forms part of that pathway rather than an afterthought.
Vasectomy sits in the same bracket. It is inexpensive, quick and increasingly normalised among couples who have decided their family is complete. Reversal requests, meanwhile, provide a small but persistent counter-market.
Practical notes follow, since urology in Korea is one of the specialties expats most often need and least often research.
You do not need a referral. Walk into a clinic, or book by phone or KakaoTalk. Bring your passport or residence card. Furthermore, if you hold national health insurance, standard consultations and most tests are inexpensive.
Ask what is covered before agreeing to anything. The line between insured and uninsured treatment decides whether you pay 100,000 won or several million. Ask directly whether a proposed procedure is geubyeo, meaning covered, or bigeubyeo, meaning not covered.
Be sceptical of premium recommendations. If a clinic proposes an expensive uncovered operation at a first visit, get a second opinion at a university hospital. This applies especially to prostate procedures, which regulators have already flagged for overuse.
English capability varies enormously. Gangnam and Yongsan clinics most often offer English consultations, and directories such as Expat Health Seoul list English-speaking urologists. University hospitals also maintain international clinics with interpreters on staff.
Get a PSA test if you are over 50. It is not part of national screening, so nobody will invite you. Add it to a private health check-up instead, where it usually costs very little. Men with a family history should start earlier.
Cash-pay pricing is genuinely competitive. Visitors comparing costs will find the same dynamic that drives Korea’s medical tourism sector and its cosmetic clinics. Equipment density is high, price menus are published, and waits are short.
The Korea urology industry splits into three layers, and conflating them produces bad conclusions.
The device layer looks strongest. Robotic platforms, laser systems, lithotripters and prostate implants all sell into a patient base that grows automatically with ageing. Consumables, notably, generate recurring revenue regardless of which clinic wins the patient.
The clinic layer looks most exposed. Single-owner practices depend on uncovered procedures reimbursed through private indemnity insurance, and that funding mechanism is being deliberately tightened. Clinics that rebuilt around one high-margin procedure have simply repeated the circumcision mistake with a different product.
The policy layer is the swing factor. National PSA screening would reshape the whole pipeline. More early diagnoses would mean more low-risk cases and less late-stage treatment. Diagnostics firms would benefit immediately, while high-end treatment volumes would eventually soften.
There is a broader lesson for anyone reading Korean healthcare from outside. The country’s cash-pay clinic sector expands wherever national insurance leaves a gap, and it contracts when regulators close one. The same mechanism drives weight-loss drug clinics, dermatology chains and orthopaedic pain centres.
Korean urology lost its defining procedure and survived by finding a bigger one. Whether the Korea urology industry has genuinely diversified, or merely swapped one dependency for another, is the question its next decade will answer.
On September 1, 2026, a hospital in Miryang will switch off its lights for the…
Last year, the single most common reason a Korean was admitted to a hospital stopped…
In spring 2026, a Korean outdoor brand put a plain T-shirt on its shelves. Nothing…
On August 7, 2026, a weather station in Seoul's Nowon district logged 40.2 degrees Celsius.…
Stand on the sand at Haeundae in early August and count the exposed shoulders. The…
On a Tuesday morning in Seoul, two people ride the same subway line in opposite…